Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults
- 25 March 2009
- Vol. 27 (47) , 6642-6648
- https://doi.org/10.1016/j.vaccine.2009.03.015
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical TrialThe Journal of Infectious Diseases, 2008
- Increasing Doses of an Inactivated Influenza A/H1N1 Vaccine Induce Increasing Levels of Cross‐Reacting Antibody to Subsequent, Antigenically Different, VariantsThe Journal of Infectious Diseases, 2008
- Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adultsVaccine, 2008
- Inactivated Whole Virus Influenza A (H5N1) Vaccine1Emerging Infectious Diseases, 2007
- Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative studyVaccine, 2007
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Flu-vaccine makers toil to boost supplyNature, 2006
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic useVirus Research, 2004
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001